Importantly, TP53 mutations or CDKN2A deletion were detected in about 50% MYC-induced B-cell lymphomas, but the concurrent DMTF1 loss resulted in much more frequent intact TP53 and CDKN2A [74]. The gene discussed is TP53; the disease is B-cell non-Hodgkin lymphoma.